SNDX Nicholas AJ. Botwood buys $106K worth of shares
May 20, 2025, 4:36 AM
0.00%
What does SNDX do
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Nicholas AJ. Botwood bought 11,765 shares of SNDX on 16 May at $8.99 per share, worth a total of $106K. They now own 35,165 SNDX shares, or a 50% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
